HCA Warning, Leqembi Shift, FTC Insulin, ICER Advice

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel like they're converging on one critical theme: the fragile sustainability of innovative therapies in real-world systems.

MarcusExactly. We're looking at HCA's profit warning — a stark signal of access erosion in US healthcare systems. Then subcutaneous Leqembi's approval — how this transforms Alzheimer's value propositions. The FTC's insulin settlement with CVS Caremark — exposing PBM pricing practices. And ICER's expanded scientific advice — aiming to de-risk development from the outset.

SaraThat second one is particularly interesting — the subcutaneous route for Leqembi might ease administration, but it doesn't automatically resolve the underlying cost-effectiveness debates. Payers will scrutinize this closely.

MarcusAbsolutely. Let's get into it.

MarcusStarting with HCA's profit warning. This major US hospital operator cited access challenges and reimbursement pressures as key drivers. It's not just about HCA — this signals systemic strain where high-cost innovative therapies collide with operational realities. The question is whether this is a temporary blip or a harbinger of broader access restrictions.

SaraThat's one read — but I'd frame it slightly differently. For payers, this isn't just about reimbursement rates; it's about the opportunity cost. When hospitals absorb losses on high-cost drugs, it diverts resources from other critical services. The budget impact ripples through the entire system.

MarcusI wonder if that's the full picture though. HCA specifically mentioned patient access barriers. This suggests the problem isn't just financial — it's about the practical logistics of delivering complex therapies. The infrastructure strain is real.

SaraFair point. But the part that gives me pause is how this interacts with Medicare reimbursement policies. When payment models don't account for the true cost of administration, hospitals face impossible choices. That's not sustainable.

MarcusRight. And from the payer side, how do you balance supporting innovation with system sustainability? There's no easy answer here.

SaraExactly. This is one of those stories where the tension between access and affordability becomes unavoidable. We'll be watching how other hospital systems respond.

MarcusShifting to subcutaneous Leqembi. The FDA's approval of this subcutaneous formulation for Alzheimer's is significant. It eliminates the IV infusion burden, potentially improving patient adherence and quality of life. For HEOR, this changes the value equation — administration costs drop, but the core efficacy evidence remains the same.

SaraWhat strikes me about that is the methodological challenge. While the route change matters operationally, the clinical benefit profile hasn't fundamentally shifted. Payers will still question whether the incremental value justifies the price, especially given the controversial evidence base.

MarcusThat's fair, though I think payers would see it differently. The real-world burden reduction is substantial. Fewer clinic visits, less nursing time — those are tangible savings that should factor into value assessments.

SaraBut those savings are hard to quantify in HTA frameworks. Most value assessments still prioritize clinical endpoints over system efficiencies. That disconnect remains problematic.

MarcusI keep coming back to how this reshapes the Alzheimer's treatment narrative. Subcutaneous administration could expand the eligible patient population beyond those who can tolerate IV therapy. That's a meaningful access improvement.

SaraAgreed — but only if the price adjusts accordingly. Without that, we're just rearranging deck chairs on a fundamentally unaffordable model. The real test will be whether NICE and other HTA bodies recognize this shift.

MarcusNo question. This story caught me off guard — the practical implications are bigger than the initial headlines suggest.

MarcusNow the FTC settlement with CVS Caremark over insulin pricing. The FTC accused CVS of anti-competitive practices in insulin distribution, leading to inflated prices. This settlement could reshape how PBMs operate and insulin is priced, potentially increasing transparency and reducing costs.

SaraThat's one read — but I'd push back slightly. While the settlement addresses specific anti-competitive behavior, it doesn't solve the underlying issue of insulin price inflation. The root causes — manufacturer pricing, rebates, and formulary access — remain unaddressed.

MarcusWhat strikes me is the precedent this sets. When regulators target PBM practices directly, it signals a shift in oversight. For HEOR teams, this means more scrutiny on rebate structures and price transparency in value dossiers.

SaraExactly. And the budget impact question here is enormous. If insulin pricing becomes more transparent, could it create a domino effect for other high-cost therapies? That's the opportunity cost angle payers will be watching.

MarcusRight. But what about the patient perspective? This settlement could lower out-of-pocket costs for insulin-dependent patients immediately. That's a tangible access improvement.

SaraAbsolutely — but the systemic effects are what matter long-term. If PBMs change their practices, how does that affect formulary placement for other drugs? The ripple effects could be significant.

MarcusThis is one of those stories where the immediate win might be just the beginning of a larger conversation about drug pricing structures.

MarcusFinally, ICER's expansion of scientific advice to include early-phase development. This initiative aims to provide HEOR guidance during clinical development, potentially aligning evidence generation with payer expectations from the outset. It could reshape how companies approach HEOR strategy.

SaraI'm curious about the timing here. If companies are using this to shape development based on payers' preferences, does that compromise innovation? Or is it a pragmatic step toward reducing late-stage failures?

MarcusThat's a fair concern. But what's interesting is how this could address the evidence generation gap. Many innovative therapies struggle with late-stage HTA hurdles because payer requirements weren't considered early enough.

SaraThe part that gives me pause is the resource implication. Smaller biotech companies might not have the bandwidth to engage with ICER at this stage. Could this create a two-tiered system for evidence development?

MarcusI wonder if that's the full picture though. ICER's model emphasizes flexibility and iterative advice. It's not about dictating development paths, but about reducing uncertainty. That could benefit everyone.

SaraFair enough. But from the payer side, the question is whether this leads to more evidence generation or just more payer-aligned evidence. The distinction matters for genuine innovation.

MarcusExactly. And this connects to something I keep coming back to — the need for earlier value dialogue in drug development. This expansion could be a step in that direction, though the long-term impact remains to be seen.

SaraAgreed. The real test will be whether this leads to more therapies reaching patients or just more efficient HTA processes.

SaraA lot to think about today. I'll be watching how the FTC settlement impacts insulin pricing transparency in the next 12 months. That could set a precedent for other high-cost therapies.

MarcusSame — and for me the thread running through today is the tension between operational realities and innovation. HCA's warning, Leqembi's shift, the FTC's action — all reflect how access is increasingly shaped by system-level pressures, not just clinical value.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.